Primary Site >> Stomach Cancer
Gene >> KDR
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. PMID: 9816116 |
Ref: Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. PMID: 9053510 |
Ref: Angiogenesis in poorly differentiated medullary carcinoma of the stomach. PMID: 9590699 |
Ref: Lymphangiogenesis in tumor tissues and 5'-Nase, Flt-4, Flk-1 expressions. PMID: 11776119 |
Ref: Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer. PMID: 11313181 Ref: Total synthesis and biological evaluation of the nakijiquinones. PMID: 11716712 Ref: Expression of vascular endothelial growth factor and its role in oncogenesis of human gastric carcinoma. PMID: 11819817 |
Ref: VEGF receptor antisense therapy inhibits angiogenesis and peritoneal dissemination of human gastric cancer in nude mice. PMID: 11857038 Ref: The role of KDR in the interactions between human gastric carcinoma cell and vascular endothelial cell. PMID: 12174363 Ref: Expression of vascular endothelial growth factor and its receptors KDR and Flt-1 in gastric cancer cells. PMID: 12439912 |
Ref: Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells. PMID: 12618892 Ref: [Expression of MMP-9 and MMP-9 mRNA in gastric carcinoma and its correlation with angiogenesis]. PMID: 12899759 |
Ref: Suppression of tumor growth and metastasis by a VEGFR-1 antagonizing peptide identified from a phage display library. PMID: 15197767 Ref: Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. PMID: 15240521 Ref: Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. PMID: 15245777 Ref: ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. PMID: 15367698 Ref: (64)Cu-1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid-quantum dot-vascular endothelial growth factor PMID: 20641777 |
Ref: Effect of Weikangning on gastric cancer cell growth and expression of vascular endothelial growth factor and its receptors KDR and Flt-1. PMID: 15742392 Ref: Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. PMID: 15743179 Ref: [Specific killing effects of adenovirus-mediated double suicide gene driven by KDR promoter on venous endothelial cells and gastric cancer cells in vitro]. PMID: 16109546 Ref: Prognostic significance of vascular endothelial growth factor D in gastric carcinoma. PMID: 16311850 Ref: Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer. PMID: 16317086 |
Ref: ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model. PMID: 16052530 Ref: Expression of vascular endothelial growth factor (VEGF)-C and -D in gastric carcinoma. PMID: 16508727 Ref: [In vitro killing effect of adenovirus-mediated fusion gene system driven by KDR promoter on gastric cancer cells]. PMID: 16624737 Ref: The effects of VEGF and VEGFR-2 on survival in patients with gastric cancer. PMID: 16761623 Ref: [Effects of weikangning contained serum on growth of gastric cancer cell, expression of vascular endothelial growth factor and its receptors including KDR and fit-1]. PMID: 17569358 |
Ref: Effect of arsenic trioxide on vascular endothelial cell proliferation and expression of vascular endothelial growth factor receptors Flt-1 and KDR in gastric cancer in nude mice. PMID: 18161919 |
Ref: Lymphatic and/or blood vessel invasion in gastric cancer: relationship with clinicopathological parameters, biological factors and prognostic significance. PMID: 17628829 Ref: Vascular endothelial growth factor receptor-3 is a favorable prognostic factor in advanced gastric carcinoma. PMID: 18357379 Ref: Wogonin suppresses tumor growth in vivo and VEGF-induced angiogenesis through inhibiting tyrosine phosphorylation of VEGFR2. PMID: 18378261 Ref: Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma. PMID: 18609713 Ref: Correlation of vascular endothelial growth factor-D expression and VEGFR-3-positive vessel density with lymph node metastasis in gastric carcinoma. PMID: 18756043 Ref: Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms. PMID: 19010837 |
Ref: Gastric cancer in the era of molecularly targeted agents: current drug development strategies. PMID: 19363621 Ref: Soluble angiogenesis markers in gastric tumor patients. PMID: 19419943 Ref: Novel investigational drugs for gastric cancer. PMID: 19466878 Ref: Anti-angiogenic therapy against gastrointestinal tract cancers. PMID: 19531544 Ref: The expression of VEGF receptor genes is concurrently influenced by epigenetic gene silencing of the genes and VEGF activation. PMID: 19633424 Ref: Vascular endothelial growth factor-D is correlated with hepatic metastasis from gastric cancer after radical gastrectomy. PMID: 19744460 Ref: The expression of VEGF receptor genes is concurrently influenced by epigenetic gene silencing of the genes and VEGF activation. PMID: 28001118 |
Ref: Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways. PMID: 20039326 Ref: Potential role for vascular endothelial growth factor-D as an autocrine factor for human gastric carcinoma cells. PMID: 20626397 Ref: [Impact of HER2, EGFR, IGF-1R, and VEGFR expressions on the outcome of chemotherapy for advanced gastric cancer]. PMID: 20716873 |
Ref: The function and mechanism of COX-2 in angiogenesis of gastric cancer cells. PMID: 21266034 Ref: Aurora-A as an independent molecular prognostic marker in gastric cancer. PMID: 21479365 Ref: The structural basis for the function of two anti-VEGF receptor 2 antibodies. PMID: 21827946 |
Ref: Stem cells with fused gene expression of cytosine deaminase and interferon-beta migrate to human gastric cancer cells and result in synergistic growth inhibition for potential therapeutic use. PMID: 22159640 Ref: Biomarkers for antitumor activity of bevacizumab in gastric cancer models. PMID: 22273502 Ref: A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. PMID: 22315472 Ref: Ad-KDRscFv:sTRAIL displays a synergistic antitumor effect without obvious cytotoxicity to normal tissues. PMID: 22406047 Ref: Current status of targeted therapies in advanced gastric cancer. PMID: 22443228 Ref: Tumor interstitial fluid and gastric cancer metastasis: an experimental study to verify the hypothesis of "tumor-phlegm microenvironment". PMID: 22549391 Ref: Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. PMID: 22565005 Ref: Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients. PMID: 22808003 Ref: Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. PMID: 22842485 |
Ref: Serum VEGF and VEGF-C values before surgery and after postoperative treatment in gastric cancer. PMID: 22855190 Ref: Blockade of VEGFR-1 and VEGFR-2 enhances paclitaxel sensitivity in gastric cancer cells. PMID: 23364970 Ref: Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PMID: 23516391 Ref: A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities. PMID: 23548264 Ref: Study of the mechanism of bystander effect of KDR-CDglyTK system mediated by adenovirus for the treatment of gastric cancer. PMID: 23605100 Ref: Ramucirumab: a novel antiangiogenic agent. PMID: 23718298 Ref: Small molecule R1498 as a well-tolerated and orally active kinase inhibitor for hepatocellular carcinoma and gastric cancer treatment via targeting angiogenesis and mitosis pathways. PMID: 23755206 Ref: S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. PMID: 23804704 Ref: siRNA-participated chemotherapy: an efficient and specific therapeutic against gastric cancer. PMID: 24077839 Ref: Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. PMID: 24090479 Ref: A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent antitumor activity. PMID: 24132142 Ref: Type II cGMP-dependent protein kinase inhibits activation of key members of the RTK family in gastric cancer cells. PMID: 24648957 |
Ref: Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. PMID: 24094768 Ref: Anti-angiogenic agent ramucirumab: meaningful or marginal? PMID: 24605771 Ref: SPARC expression is negatively correlated with clinicopathological factors of gastric cancer and inhibits malignancy of gastric cancer cells. PMID: 24676680 Ref: An updated review of gastric cancer in the next-generation sequencing era: insights from bench to bedside and vice versa. PMID: 24744582 Ref: Ramucirumab: first global approval. PMID: 24916147 Ref: Ramucirumab for metastatic gastric or gastroesophageal junction cancer: results and implications of the REGARD trial. PMID: 25145426 Ref: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. PMID: 25240821 Ref: Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification. PMID: 25249557 |
Ref: Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: preclinical and clinical aspects. PMID: 24970311 Ref: Targeted therapy in gastric cancer. PMID: 25706252 Ref: Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight. PMID: 25800976 Ref: Gastric cancer-associated enhancement of von Willebrand factor is regulated by vascular endothelial growth factor and related to disease severity. PMID: 25886574 Ref: Effects of gene silencing of CypB on gastric cancer cells. PMID: 25975506 Ref: Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors. PMID: 26020064 Ref: Emerging kinase inhibitors of the treatment of gastric cancer. PMID: 26021342 Ref: The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives. PMID: 26190526 Ref: [Current standards in the treatment of gastric cancer]. PMID: 26261926 Ref: Delineation of gastric cancer subtypes by co-regulated expression of receptor tyrosine kinases and chemosensitivity genes. PMID: 26396673 Ref: Clinical utility of ramucirumab in advanced gastric cancer. PMID: 26451083 Ref: Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer. PMID: 26514182 Ref: The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer. PMID: 26807318 |
Ref: Gastric Carcinoma at the Era of Targeted Therapies. PMID: 25944013 Ref: Cancer-associated fibroblasts promote angiogenesis in gastric cancer through galectin-1 expression. PMID: 26323258 Ref: Systemic therapy beyond first-line in advanced gastric cancer: An overview of the main randomized clinical trials. PMID: 26697987 Ref: Targeted therapy for gastric cancer: Current status and future directions (Review). PMID: 26718131 Ref: DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models. PMID: 26768619 Ref: Neuropilin-1 is associated with clinicopathology of gastric cancer and contributes to cell proliferation and migration as multifunctional co-receptors. PMID: 26795388 Ref: Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. PMID: 26797419 Ref: Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application. PMID: 26880889 Ref: Ramucirumab Clinical Development: an Emerging Role in Gastrointestinal Tumors. PMID: 26887374 Ref: Interleukin-8: A potent promoter of angiogenesis in gastric cancer. PMID: 26893688 Ref: Clinical impact of tumour biology in the management of gastroesophageal cancer. PMID: 26925958 Ref: Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin). PMID: 26983912 Ref: Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays. PMID: 27001313 Ref: Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis. PMID: 27049350 Ref: Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis. PMID: 27058891 Ref: Peripheral trafficking of bone-marrow-derived stem cells in patients with different types of gastric neoplasms. PMID: 27141380 Ref: Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies. PMID: 27149032 Ref: Recent insights in the therapeutic management of patients with gastric cancer. PMID: 27156069 Ref: Gastric cancer. PMID: 27156933 Ref: Stromal-Based Signatures for the Classification of Gastric Cancer. PMID: 27197264 Ref: Personalised Treatment in Gastric Cancer: Myth or Reality? PMID: 27215435 Ref: Xiaotan Sanjie decoction inhibits angiogenesis in gastric cancer through Interleukin-8-linked regulation of the vascular endothelial growth factor pathway. PMID: 27224240 Ref: Endocan-expressing microvessel density as a prognostic factor for survival in human gastric cancer. PMID: 27340359 Ref: Incidence and risk of hypertension associated with ramucirumab in cancer patients: A systematic review and meta-analysis. PMID: 27461650 Ref: The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer. PMID: 27539855 Ref: The safety and efficacy of ramucirumab in combination with paclitaxel for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma. PMID: 27582051 Ref: Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. PMID: 27623234 Ref: Effect of colorectal cancer on the number of normal stem cells circulating in peripheral blood. PMID: 27779706 Ref: [Research status quo and progression in targeted therapy for advanced gastric cancer]. PMID: 27781258 Ref: Expression of semaphorin 6D and its receptor plexin-A1 in gastric cancer and their association with tumor angiogenesis. PMID: 27895757 Ref: Tumor profiling of co-regulated receptor tyrosine kinase and chemoresistant genes reveal different targeting options for lung and gastroesophageal cancers. PMID: 28078044 |
Ref: Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates Apatinib treatment efficacy in gastric cancer. PMID: 28061477 Ref: Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma. PMID: 28176910 Ref: [Novel pharmaceutical treatment approaches for gastric cancer]. PMID: 28220199 Ref: Anticancer and anti-angiogenic activities of extract from Actinidia eriantha Benth root. PMID: 28323051 Ref: Efficacy and safety of different molecular targeted agents based on chemotherapy for gastric cancer patients treatment: a network meta-analysis. PMID: 28477027 Ref: Gastrointestinal cancer cells treatment with bevacizumab activates a VEGF autoregulatory mechanism involving telomerase catalytic subunit hTERT via PI3K-AKT, HIF-1alpha and VEGF receptors. PMID: 28594907 Ref: Biologic therapy in esophageal and gastric malignancies: current therapies and future directions. PMID: 28736629 Ref: Angiogenesis inhibitors in early development for gastric cancer. PMID: 28770623 Ref: Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation. PMID: 28894382 Ref: Targeted therapies for gastric cancer: failures and hopes from clinical trials. PMID: 28915702 Ref: Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma. PMID: 29029508 Ref: Prion Protein Family Contributes to Tumorigenesis via Multiple Pathways. PMID: 29052140 Ref: A case of ramucirumab-related gastrointestinal perforation in gastric cancer with small bowel metastasis. PMID: 29260338 Ref: Isoprenaline/beta2-AR activates Plexin-A1/VEGFR2 signals via VEGF secretion in gastric cancer cells to promote tumor angiogenesis. PMID: 29262812 Ref: Chromosomal breaks at FRA18C: association with reduced DOK6 expression, altered oncogenic signaling and increased gastric cancer survival. PMID: 29872697 |
Ref: SOMCL-085, a novel multi-targeted FGFR inhibitor, displays potent anticancer activity in FGFR-addicted human cancer models. PMID: 28905937 Ref: Tanshinone IIA inhibits gastric carcinoma AGS cells by decreasing the protein expression of VEGFR and blocking Ras/Raf/MEK/ERK pathway. PMID: 29393362 Ref: Astragalus polysaccharide enhanced antitumor effects of Apatinib in gastric cancer AGS cells by inhibiting AKT signalling pathway. PMID: 29428665 Ref: Efficacy and safety of targeting VEGFR drugs in treatment for advanced or metastatic gastric cancer: a systemic review and meta-analysis. PMID: 29487720 Ref: VEGFR-2 as a novel predictor of survival in gastric cancer: A systematic review and meta-analysis. PMID: 29572120 Ref: [Predictive diagnostics of gastric cancer in 2018]. PMID: 29631408 Ref: Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers. PMID: 29663291 Ref: VEGFA and VEGFR2 RNAscope determination in gastric cancer. PMID: 29761299 Ref: Contrast-enhanced computed tomography combined with Chitosan-Fe3O4 nanoparticles targeting fibroblast growth factor receptor and vascular endothelial growth factor receptor in the screening of early esophageal cancer. PMID: 29805549 Ref: Apatinib as targeted therapy for sarcoma. PMID: 29849960 Ref: Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report. PMID: 29855279 Ref: Long-term progression-free survival of third-line apatinib in lung squamous cell carcinoma. PMID: 30038504 Ref: CT textural analysis of gastric cancer: correlations with immunohistochemical biomarkers. PMID: 30087428 Ref: Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8(+) T cells in the tumor microenvironment. PMID: 30314524 Ref: The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis. PMID: 30323627 Ref: The safety of apatinib for the treatment of gastric cancer. PMID: 30324820 Ref: Anti-PD-1 Antibody SHR-1210 combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study. PMID: 30348638 Ref: Fruquintinib: First Global Approval. PMID: 30357594 Ref: The VEGFR-2 protein and the VEGFR-2 rs1870377 A>T genetic polymorphism are prognostic factors for gastric cancer. PMID: 30380970 |